The aim of the study is to investigate factors that may cause radiation-induced lung disease (RILD) in patients undergoing stereotactic body radiotherapy (SBRT) for lung tumors. Medical records of patients treated between May 2018 and June 2019 with SBRT were retrospectively evaluated. All patients should have a diagnosis of either primary non-small cell lung cancer (NSCLC) or less than three metastases to lung from another primary. The median treatment dose was 50 Gy in 4–5 fractions. Tumor response and RILD were evaluated in thoracic computer tomography (CT) using RECIST criteria. 82 patients with 97 lung lesions were treated. The median age was 68 years (IQR = 62–76). With a median follow-up of 7.2 months (3–18 months), three patients had grade 3 radiation pneumonitis (RP). RILD was observed in 52% of cases. Patients who had RILD had a higher risk of symptomatic RP (p = 0.007). In multivariate analyses older age, previous lung radiotherapy history, and median planning treatment volume (PTV) D95 value of ≥ 48 Gy were associated with RILD. Local recurrence (LR) was observed in 5.1% of cases. There was no difference in overall survival and LR with the presence of RILD. Older age, previous lung radiotherapy history, and median PTV D95 value of ≥ 48 Gy seems to be associated with post-SBRT RILD.

这项研究的目的是调查在接受针对肺癌的立体定向放射疗法（SBRT）的患者中可能引起放射诱发的肺部疾病（RILD）的因素。回顾性评估了2018年5月至2019年6月间用SBRT治疗的患者的病历。所有患者均应诊断为原发性非小细胞肺癌（NSCLC）或从另一原发灶转移至肺部的转移少于三个。中位治疗剂量为4-5个分数，为50 Gy。使用RECIST标准在胸部计算机断层扫描（CT）中评估肿瘤反应和RILD。治疗82例97例肺部病变。中位年龄为68岁（IQR = 62-76）。中位随访时间为7.2个月（3-18个月），其中3例患有3级放射性肺炎（RP）。在52％的病例中观察到RILD。p  = 0.007）。在多变量分析中，年龄，以前的肺部放疗史以及中位计划治疗量（PTV）D95≥48 Gy与RILD相关。在5.1％的病例中观察到局部复发（LR）。有RILD时，总生存率和LR无差异。老年人，先前的肺放疗史和PTV D95中值≥48 Gy似乎与SBRT后RILD有关。